The disposable plastic circuit that carries a dialysis patient's blood out of the body and back again has new federal testing recommendations attached to it for the first time since 2008.
FDA released a revised final guidance for hemodialysis blood tubing sets on July 23, spelling out what manufacturers should submit when they seek clearance to market these sets. The agency said the recommendations are "intended to promote consistency and facilitate efficient review" of the submissions it receives.
The population this touches is large and largely invisible in health coverage. As of March 31, 2025, dialysis facilities in the United States and its territories were treating 516,837 patients, of whom 433,396 received in-center hemodialysis, according to the National Forum of ESRD Networks. Most of them sit for treatment three times a week, every week, indefinitely. Each session runs their entire blood volume through one of these sets, repeatedly.
What a Blood Tubing Set Does, and What Failure Looks Like
A blood tubing set is not one tube. It is an assembly: an arterial line carrying blood from the patient to the dialyzer, a venous line carrying it back, plus drip chambers, clamps, injection ports, heparin lines, transducer protectors and connectors.
The regulation covering it, 21 CFR 876.5820, describes the extracorporeal blood system as tubing, pumps, pressure monitors, air or bubble detectors, and alarms that keep blood moving safely between the patient and the dialyzer. The guidance applies to that circuit under product codes FJK and KOC. It does not cover dialysis catheters or peritoneal dialysis tubing.
Failure modes are mechanical and specific. Tubing can kink, which crushes red blood cells as they pass through the narrowed section. FDA's guidance recommends that manufacturers include a warning that significant destruction of red blood cells can occur in kinked tubing, and it singles out the segment just after the blood pump as the highest-risk location. Connections can loosen, allowing air to enter the circuit or blood to leak out. Clamps can fail to fully occlude a line. Transducer protectors can leak, contaminating the machine's pressure sensors.
What the Revised Guidance Asks Manufacturers to Prove
The document is not a rulebook. FDA guidance describes the agency's current thinking and is explicitly nonbinding, and a company may propose an alternative approach.
Within that framing, the recommendations are unusually concrete. FDA suggests testing three or more sets of every model, with pressure leak testing at 1.5 times the maximum labeled positive and negative pressures, endurance testing of the pump segment at maximum labeled blood flow, and transducer protector testing at twice the maximum labeled pressure. It recommends clamp occlusion testing, tensile testing of every joint, priming volume assessment, and kink resistance testing after repeated clamping.
It also recommends running a set on each compatible dialysis machine for four hours at body temperature using a blood analog fluid, inspecting for kinks across the full length of tubing and across a range of dialyzer sizes.
On materials, FDA asks manufacturers to disclose colorants, additives, and plasticizers, including DEHP, and it treats these sets as long-term blood-contacting devices, which triggers the fuller biocompatibility panel. On sterility, it recommends a sterility assurance level of one in a million along with endotoxin testing. On labeling, it recommends color coding, red connectors for the arterial line and blue for the venous line, plus a single-use statement and an expiration date.
The honest characterization matters here. FDA's own guidance history describes this as a Level 2 revision that harmonizes the document with the agency's updated biocompatibility standard and removes outdated submission format language. It is a technical refresh of an eighteen-year-old document, not a response to a new safety crisis.
The Recall That Shows Why These Details Are Not Academic
Three months before the guidance was issued, FDA classified a correction affecting hemodialysis bloodlines as its most serious recall type.
B. Braun Medical issued an urgent correction covering certain Streamline Airless System and B3 Low Volume bloodlines after identifying tubing changes that could allow air bubbles to form during treatment. FDA warned that patients could experience moderate blood loss if blood in the circuit could not be safely returned, and that in some patients blood loss can lead to life-threatening events including death.
The company recommended that facilities use unaffected sets or alternate equipment where possible; where no alternative existed, follow connection instructions precisely; increase visual inspection of the lines during treatment; and stop and replace the set if leakage or air entry could not be resolved. As of March 20, 2026, no serious injuries or deaths had been reported in connection with the issue.
That sequence is the argument for the guidance. The defect was a design and manufacturing detail invisible to the patient in the chair. It surfaced through post-market reporting rather than pre-market testing.
Who Carries the Risk, and What Families Can Reasonably Do
Risk is not evenly distributed across the dialysis population. More than 808,000 people in the United States live with end-stage kidney disease, and roughly 68 percent are on dialysis rather than carrying a functioning transplant, according to NIDDK. Within that group, the people most exposed to a device failure are those on home hemodialysis, where no clinical staff is present to catch a problem in real time, and patients treated at facilities with a single equipment supplier and no ready alternative.
Nothing about this guidance calls for a change in anyone's treatment. Patients should not skip or shorten sessions, and missed dialysis carries far greater immediate danger than any device issue described here.
What is reasonable is to ask the clinic which bloodline sets it uses and whether any are covered by an open FDA correction, to report any observed leak, alarm pattern or visible air in the lines to staff during treatment rather than after, and for home hemodialysis patients, to confirm they have current instructions for the specific set in their supply. Sudden shortness of breath, chest pain, confusion, or a rapid drop in blood pressure during a session requires immediate attention from staff or emergency services.
What Happens Next
FDA accepts comments on the guidance at any time through docket FDA-2026-D-1877. Going forward, new 510(k) clearances for blood tubing sets will be reviewed against these recommendations, and any further recalls or corrections will appear in the agency's device recall database.
The confirmed development is that the FDA has updated its testing and labeling recommendations for hemodialysis blood tubing sets after eighteen years. The people most affected are the more than 430,000 Americans receiving in-center hemodialysis and their care teams. The most reasonable action is to keep every scheduled session and raise equipment questions with the clinic. The central uncertainty is whether nonbinding recommendations change manufacturing practice quickly enough to prevent the next correction.
Frequently Asked Questions
What did FDA release? Revised final guidance describing the testing, sterility, materials and labeling information manufacturers should include when seeking clearance for hemodialysis blood tubing sets.
Is this because something went wrong? Not directly. FDA describes the update as a technical revision harmonizing the document with its current biocompatibility standard. A separate serious recall involving bloodlines was classified in April 2026.
Does this change my dialysis treatment? No. Nothing in the guidance requires any change to a patient's prescription, schedule, or clinic. Missing sessions is far more dangerous than the risks discussed here.
What is a blood tubing set? The disposable tubing circuit that carries blood from the patient to the dialyzer and back, including clamps, drip chambers, ports and connectors. It does not include the catheter or vascular access.
What should I watch for during a session? Visible air in the lines, leaking at connections, repeated machine alarms, or a sudden drop in blood pressure. Tell staff during treatment rather than waiting.
Are home dialysis patients at higher risk? Home hemodialysis lacks on-site clinical staff to catch a technical problem immediately. Patients on home therapy should keep current instructions for their specific set and know their clinic's after-hours contact.
Is FDA guidance legally binding? No. Guidance documents describe the agency's current thinking and are recommendations. Manufacturers may propose alternative approaches that meet statutory requirements.
